EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Biomarkers

Background:

• Fascin-1 (FSCN1) is implicated in various cancers and may indicate aggressiveness.
• The regulatory mechanisms of FSCN1 in triple-negative breast cancer (TNBC) cell invasion and migration are not well understood.

Purpose of the Study:

• To investigate the role of FSCN1 in TNBC cell invasion and migration.
• To explore the regulatory pathway of FSCN1 in TNBC.
• To assess the prognostic value of FSCN1 in breast cancer patients.

Main Methods:

• Comparative analysis of FSCN1 expression in different breast cancer subtypes and stages.
• In vitro studies using cell lines to assess the impact of FSCN1 overexpression on migration and invasion.
• Investigating the role of epidermal growth factor (EGF) and MAPK signaling in FSCN1 regulation.
• Evaluating the combined effect of FSCN1 siRNA and Gefitinib on FSCN1 expression.
• Statistical analysis of the association between FSCN1 expression and patient survival outcomes.

Main Results:

• FSCN1 expression is significantly higher in invasive ductal carcinoma than in pre-invasive lesions.
• FSCN1 is significantly upregulated in TNBC compared to non-TNBC subtypes.
• FSCN1 overexpression enhances TNBC cell migration and invasion.
• Epidermal growth factor (EGF) induces FSCN1 expression via MAPK activation, promoting cell motility.
• Combined treatment with FSCN1 siRNA and Gefitinib more effectively reduces FSCN1 expression than monotherapy.
• Elevated FSCN1 expression correlates with poor relapse-free and overall survival.

Conclusions:

• FSCN1 plays a critical role in promoting TNBC cell invasion and migration.
• The EGF/MAPK pathway regulates FSCN1 expression in TNBC.
• FSCN1 is a potential prognostic biomarker for TNBC.
• Co-targeting the epidermal growth factor receptor and FSCN1 presents a promising therapeutic strategy for TNBC.